|

V001-BCMA Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Tongji Hospital1

Indications

  • Recurrent or Refractory ANCA Associated Vasculitis1
  • Recurrent or Refractory Idiopathic Inflammatory Myopathy1
  • Recurrent or Refractory Systemic Sclerosis1
  • Recurrent or Refractory IgG4 Related Diseases1
  • Recurrent or Refractory Systemic Lupus Erythematosus1

Other1 trial

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.